Show simple item record

dc.contributor.authorDighe, Ketan
dc.contributor.authorMoitra, Parikshit
dc.contributor.authorAlafeef, Maha
dc.contributor.authorGunaseelan, Nivetha
dc.contributor.authorPan, Dipanjan
dc.date.accessioned2022-01-19T16:05:52Z
dc.date.available2022-01-19T16:05:52Z
dc.date.issued2021-12-18
dc.identifier.urihttp://hdl.handle.net/10713/17597
dc.description.abstractThe coronavirus disease 2019 (COVID-19) pandemic has highlighted the major shortcoming of healthcare systems globally in their inability to diagnose the disease rapidly and accurately. At present, the molecular approaches for diagnosing COVID-19 primarily use reverse transcriptase polymerase chain reaction (RT-PCR) to create and amplify cDNA from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. Although molecular tests are reported to be specific, false negatives are quite common. Furthermore, literally all these tests require a step involving RNA isolation which does not make them point-of-care (POC) in the true sense. Here, we report a lateral flow strip-based RNA extraction and amplification-free nucleic acid test (NAT) for rapid diagnosis of positive COVID-19 cases at POC. The assay uses highly specific 6-carboxyfluorescein (6-FAM) and biotin labeled antisense oligonucleotides (ASOs) as probes those are designed to target N-gene sequence of SARS-CoV-2. Additionally, we utilized cysteamine capped gold-nanoparticles (Cyst-AuNPs) to augment the signal further for enhanced sensitivity. Without any large-stationary equipment and highly trained staffers, the entire sample-to-answer approach in our case would take less than 30 min from a patient swab sample collection to final diagnostic result. Moreover, when evaluated with 60 clinical samples and verified with an FDA-approved TaqPath RT-PCR kit for COVID-19 diagnosis, the assay obtained almost 99.99% accuracy and specificity. We anticipate that the newly established low-cost amplification-free detection of SARS-CoV-2 RNA will aid in the development of a platform technology for rapid and POC diagnosis of COVID-19 and other pathogens.en_US
dc.description.urihttps://doi.org/10.1016/j.bios.2021.113900en_US
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofBiosensors & Bioelectronicsen_US
dc.rightsCopyright © 2021 Elsevier B.V. All rights reserved.en_US
dc.subjectAntisense oligonucleotideen_US
dc.subjectCOVID-19en_US
dc.subjectGold-nanoparticlesen_US
dc.subjectLateral flow assayen_US
dc.subjectPoint-of-careen_US
dc.subjectSARS-CoV-2en_US
dc.titleA rapid RNA extraction-free lateral flow assay for molecular point-of-care detection of SARS-CoV-2 augmented by chemical probes.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.bios.2021.113900
dc.identifier.pmid34959185
dc.source.journaltitleBiosensors & bioelectronics
dc.source.volume200
dc.source.beginpage113900
dc.source.endpage
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record